Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam
Sponsor: Lundbeck LLC
Terminated
Recruitment Issues - Lack of target population
Other terminated trials from Lundbeck LLC
More terminations from Lundbeck LLC
Other Epilepsia Partialis Continua trials with similar outcome
A PHASE3 clinical study on Epilepsia Partialis Continua and Epilepsy, this trial is terminated or withdrawn. The trial is conducted by Lundbeck LLC and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lundbeck LLC
- The Cooper Health System
For direct contact, visit the study record on ClinicalTrials.gov .